Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Venn

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
The Journal of Molecular Diagnostics : JMD|March 28, 2009
Sensitive and specific measurement of minimal residual disease in acute lymphoblastic leukemiaAlexander A Morley, Sue Latham, Michael J Brisco, et al.
Cancer Letters|September 4, 2017
Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesionsTeresa Sadras, Susan L Heatley, Chung H Kok, et al.
British Journal of Haematology|February 23, 2021
CKLF and IL1B transcript levels at diagnosis are predictive of relapse in children with pre-B-cell acute lymphoblastic leukaemiaStephen Fitter, Alanah L Bradey, Chung Hoow Kok, et al.
Leukemia|December 14, 2011
Highly sensitive MRD tests for ALL based on the IKZF1 Δ3-6 microdeletionN C Venn, V H J van der Velden, M de Bie, et al.
American Journal of Disaster Medicine|February 18, 2025
Efficacy of ex vivo decontamination methods for chemical warfare agents on military working dog (Canis familiaris) cadaver skin tissueEmilee C Venn, Jarrod A Miller, Shawn M Stevenson, et al.
The Journal of Molecular Diagnostics : JMD|March 28, 2009
Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemiaMichael J Brisco, Sue Latham, Rosemary Sutton, et al.
British Journal of Cancer|September 2, 2021
Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcomaVinod Vijay Subhash, Libby Huang, Alvin Kamili, et al.
British Journal of Haematology|December 2, 2017
A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in childrenRosemary Sutton, Nicola C Venn, Tamara Law, et al.
Pediatric Blood & Cancer|February 27, 2021
Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomabRosemary Sutton, Luciano Dalla Pozza, Seong Lin Khaw, et al.
Blood Advances|March 10, 2020
The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemiaLauren M Brown, Andrew Lonsdale, Andrea Zhu, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
The Journal of Molecular Diagnostics : JMD|March 28, 2009
Sensitive and specific measurement of minimal residual disease in acute lymphoblastic leukemiaAlexander A Morley, Sue Latham, Michael J Brisco, et al.
Cancer Letters|September 4, 2017
Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesionsTeresa Sadras, Susan L Heatley, Chung H Kok, et al.
British Journal of Haematology|February 23, 2021
CKLF and IL1B transcript levels at diagnosis are predictive of relapse in children with pre-B-cell acute lymphoblastic leukaemiaStephen Fitter, Alanah L Bradey, Chung Hoow Kok, et al.
Leukemia|December 14, 2011
Highly sensitive MRD tests for ALL based on the IKZF1 Δ3-6 microdeletionN C Venn, V H J van der Velden, M de Bie, et al.
American Journal of Disaster Medicine|February 18, 2025
Efficacy of ex vivo decontamination methods for chemical warfare agents on military working dog (Canis familiaris) cadaver skin tissueEmilee C Venn, Jarrod A Miller, Shawn M Stevenson, et al.
The Journal of Molecular Diagnostics : JMD|March 28, 2009
Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemiaMichael J Brisco, Sue Latham, Rosemary Sutton, et al.
British Journal of Cancer|September 2, 2021
Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcomaVinod Vijay Subhash, Libby Huang, Alvin Kamili, et al.
British Journal of Haematology|December 2, 2017
A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in childrenRosemary Sutton, Nicola C Venn, Tamara Law, et al.
Pediatric Blood & Cancer|February 27, 2021
Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomabRosemary Sutton, Luciano Dalla Pozza, Seong Lin Khaw, et al.
Blood Advances|March 10, 2020
The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemiaLauren M Brown, Andrew Lonsdale, Andrea Zhu, et al.
Pageof 5